The recent recall of 8 lots of injectable cancer drugs, some of which Mylan ($MYL) made for client Pfizer ($PFE), was just a prelude to an FDA warning letter, it turns out. The agency today posted the letter, aimed at three plants in India that Mylan got in its deal for Agila Specialties two years ago. The FDA said it knew Mylan had only recently bought the plants when the inspections started last year, but said the company should have picked up on the contamination concerns before the FDA had to step in. The action led Mylan CEO Heather Bresch to issue a statement that the company was committed to high standards and would address the issues. Story | More